Antisense HIV-1 therapy - Enzo Therapeutics

Drug Profile

Antisense HIV-1 therapy - Enzo Therapeutics

Alternative Names: HGTV-43; StealthVector®HGTV43™

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Enzo Therapeutics
  • Class Antisense oligonucleotides; Antivirals; Gene therapies; Stem cell therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 09 Sep 2016 Phase-II clinical trials in HIV-1 infections in USA (Parenteral) before September 2016 (Enzo Biochem pipeline, September 2016)
  • 07 Jan 2016 Phase-I/II development for HIV-1 infections is ongoing in USA
  • 21 Sep 2015 Phase-I/II development for HIV-1 infections is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top